Clarity Medical posts ~30% YoY revenue rebound; resumption roadmap advances but trading remains suspended

Clarity Medical Group Holding Limited released a quarterly operational update on 14 July 2026, highlighting a sustained recovery in core ophthalmic services and detailing progress toward meeting Hong Kong Stock Exchange resumption requirements.

The Group reported that monthly revenue for April-June 2026 grew about 30% year-on-year, supported by its comprehensive suite of refractive treatments—SMILE, SMILE Pro, LASIK, SILK and ICL—and the recent introduction of Alcon’s Unity VCS surgical platform. Internal data indicate the company continues to perform the highest volume of ICL surgeries in Hong Kong while expanding share in laser vision correction procedures.

Management stressed stricter cost discipline. Following dismissal of earlier legal proceedings, professional fees are expected to decline materially. Additional initiatives are being implemented to streamline day-to-day operations and optimise the cost structure. The company affirmed that cash reserves and liquidity remain adequate for ordinary course requirements despite the trading halt initiated on 15 April 2025.

Resumption progress is advancing across seven guidance areas set by the Stock Exchange: • Allegations Investigation & Remedial Guidance – The FTI investigation found no evidence of fraudulent or dishonest acts by current directors or senior management; GT Advisory’s probe into IPO prospectus disclosures is nearing completion. • Integrity Guidance – The Board believes current management poses no integrity risk to investors. • Internal Control Guidance – A Big Four adviser has substantially completed an independent review; extensive enhancement measures have been implemented. • Corporate Governance Guidance – Full compliance confirmed as of 14 April 2026. • Disclosure Guidance – Ongoing adherence confirmed. • Financial Reporting Guidance – New auditor Crowe has made substantial progress on the delayed FY 2025 and FY 2026 financial statements; publication will follow completion. • Rule 13.24 Guidance – Substantive operations continue, and audited financials will further evidence compliance.

Trading in Clarity Medical shares (stock code 01406) remains suspended pending fulfilment of all resumption conditions. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.